Alpha 2.0

» Articles » PMID: 32582770

E3 Ubiquitin Ligases As Immunotherapeutic Target in Atherosclerotic Cardiovascular Disease

Overview

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2020 Jun 26

PMID 32582770

Citations 3

Authors

Authors

Kikkie Poels

Winnie G Vos

Esther Lutgens

Tom T P Seijkens

Affiliations

Affiliations

Soon will be listed here.

Abstract

Chronic low-grade inflammation drives atherosclerosis and despite optimal pharmacological treatment of classical cardiovascular risk factors, one third of the patients with atherosclerotic cardiovascular disease has elevated inflammatory biomarkers. Additional anti-inflammatory strategies to target this residual inflammatory cardiovascular risk are therefore required. T-cells are a dominant cell type in human atherosclerotic lesions. Modulation of T-cell activation is therefore a potential strategy to target inflammation in atherosclerosis. Ubiquitination is an important regulatory mechanism of T-cell activation and several E3 ubiquitin ligases, including casitas B-lineage lymphoma proto-oncogene B (Cbl-B), itchy homolog (Itch), and gene related to anergy in lymphocytes (GRAIL), function as a natural brake on T-cell activation. In this review we discuss recent insights on the role of Cbl-B, Itch, and GRAIL in atherosclerosis and explore the therapeutic potential of these E3 ubiquitin ligases in cardiovascular medicine.

Citing Articles

Cardiotoxicity of Chemotherapy: A Multi-OMIC Perspective.

Ma Y, Grootaert M, Sewduth R J Xenobiot. 2025; 15(1.

PMID: 39846541 PMC: 11755476. DOI: 10.3390/jox15010009.

CBL-b E3 ligase-mediated neddylation and activation of PARP-1 induce vascular calcification.

Kwon D, Shin S, Nam Y, Choe N, Lim Y, Jeong A Exp Mol Med. 2024; 56(10):2246-2259.

PMID: 39349831 PMC: 11541702. DOI: 10.1038/s12276-024-01322-y.

Transient increase in atherosclerotic plaque macrophage content following pneumonia in ApoE-deficient mice.

Bazaz R, Marriott H, Wright C, Chamberlain J, West L, Gelsthorpe C Front Cell Infect Microbiol. 2023; 13:1090550.

PMID: 37033482 PMC: 10076735. DOI: 10.3389/fcimb.2023.1090550.

A versatile new tool derived from a bacterial deubiquitylase to detect and purify ubiquitylated substrates and their interacting proteins.

Zhang M, Berk J, Mehrtash A, Kanyo J, Hochstrasser M PLoS Biol. 2022; 20(6):e3001501.

PMID: 35771886 PMC: 9278747. DOI: 10.1371/journal.pbio.3001501.

References

1.

Galbas T, Raymond M, Sabourin A, Bourgeois-Daigneault M, Guimont-Desrochers F, Yun T . MARCH1 E3 Ubiquitin Ligase Dampens the Innate Inflammatory Response by Modulating Monocyte Functions in Mice. J Immunol. 2016; 198(2):852-861. DOI: 10.4049/jimmunol.1601168. View

2.

Kobashigawa Y, Tomitaka A, Kumeta H, Noda N, Yamaguchi M, Inagaki F . Autoinhibition and phosphorylation-induced activation mechanisms of human cancer and autoimmune disease-related E3 protein Cbl-b. Proc Natl Acad Sci U S A. 2011; 108(51):20579-84. PMC: 3251137. DOI: 10.1073/pnas.1110712108. View

3.

Qiu L, Joazeiro C, Fang N, Wang H, Elly C, Altman Y . Recognition and ubiquitination of Notch by Itch, a hect-type E3 ubiquitin ligase. J Biol Chem. 2000; 275(46):35734-7. DOI: 10.1074/jbc.M007300200. View

4.

Xiao Y, Qiao G, Tang J, Tang R, Guo H, Warwar S . Protein Tyrosine Phosphatase SHP-1 Modulates T Cell Responses by Controlling Cbl-b Degradation. J Immunol. 2015; 195(9):4218-27. PMC: 4610872. DOI: 10.4049/jimmunol.1501200. View

5.

Liu Q, Zhou H, Langdon W, Zhang J . E3 ubiquitin ligase Cbl-b in innate and adaptive immunity. Cell Cycle. 2014; 13(12):1875-84. PMC: 4111751. DOI: 10.4161/cc.29213. View

6.

Kumar S, Naqvi R, Khanna N, Rao D . Disruption of HLA-DR raft, deregulations of Lck-ZAP-70-Cbl-b cross-talk and miR181a towards T cell hyporesponsiveness in leprosy. Mol Immunol. 2011; 48(9-10):1178-90. DOI: 10.1016/j.molimm.2011.02.012. View

7.

Bachmaier K, Toya S, Gao X, Triantafillou T, Garrean S, Park G . E3 ubiquitin ligase Cblb regulates the acute inflammatory response underlying lung injury. Nat Med. 2007; 13(8):920-6. DOI: 10.1038/nm1607. View

8.

Chiang J, Jang I, Hodes R, Gu H . Ablation of Cbl-b provides protection against transplanted and spontaneous tumors. J Clin Invest. 2007; 117(4):1029-36. PMC: 1810570. DOI: 10.1172/JCI29472. View

9.

Gomez-Martin D, Ibarra-Sanchez M, Romo-Tena J, Cruz-Ruiz J, Esparza-Lopez J, Galindo-Campos M . Casitas B lineage lymphoma b is a key regulator of peripheral tolerance in systemic lupus erythematosus. Arthritis Rheum. 2013; 65(4):1032-42. DOI: 10.1002/art.37833. View

10.

Shi Z, Li X, Hao L, Zhao Y, Wang Y, Dong B . Cbl-b gene silencing in splenic T lymphocytes as a therapeutic strategy to target the prostate cancer RM-1 cell tumors in immune competent mice. Eur Rev Med Pharmacol Sci. 2015; 18(24):3819-30. View

11.

van de Veerdonk F, Netea M . CBLB ubiquitin ligase: a major regulator of antifungal immunity. Nat Med. 2016; 22(8):834-5. DOI: 10.1038/nm.4160. View

12.

Bruening J, Lasswitz L, Banse P, Kahl S, Marinach C, Vondran F . Hepatitis C virus enters liver cells using the CD81 receptor complex proteins calpain-5 and CBLB. PLoS Pathog. 2018; 14(7):e1007111. PMC: 6053247. DOI: 10.1371/journal.ppat.1007111. View

13.

Taylor J, Krawczyk C, Mohrs M, Pearce E . Th2 cell hyporesponsiveness during chronic murine schistosomiasis is cell intrinsic and linked to GRAIL expression. J Clin Invest. 2009; 119(4):1019-28. PMC: 2662551. DOI: 10.1172/JCI36534. View

14.

Ebner P, Versteeg G, Ikeda F . Ubiquitin enzymes in the regulation of immune responses. Crit Rev Biochem Mol Biol. 2017; 52(4):425-460. PMC: 5490640. DOI: 10.1080/10409238.2017.1325829. View

15.

Bullenkamp J, Dinkla S, Kaski J, Dumitriu I . Targeting T cells to treat atherosclerosis: odyssey from bench to bedside. Eur Heart J Cardiovasc Pharmacother. 2016; 2(3):194-9. PMC: 4907356. DOI: 10.1093/ehjcvp/pvw001. View

16.

Chiang Y, Kole H, Brown K, Naramura M, Fukuhara S, Hu R . Cbl-b regulates the CD28 dependence of T-cell activation. Nature. 2000; 403(6766):216-20. DOI: 10.1038/35003235. View

17.

Tardif J, Kouz S, Waters D, Bertrand O, Diaz R, Maggioni A . Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019; 381(26):2497-2505. DOI: 10.1056/NEJMoa1912388. View

18.

Ridker P . From CANTOS to CIRT to COLCOT to Clinic: Will All Atherosclerosis Patients Soon Be Treated With Combination Lipid-Lowering and Inflammation-Inhibiting Agents?. Circulation. 2020; 141(10):787-789. DOI: 10.1161/CIRCULATIONAHA.119.045256. View

19.

Shamim M, Nanjappa S, Singh A, Plisch E, Leblanc S, Walent J . Cbl-b regulates antigen-induced TCR down-regulation and IFN-gamma production by effector CD8 T cells without affecting functional avidity. J Immunol. 2007; 179(11):7233-43. DOI: 10.4049/jimmunol.179.11.7233. View

20.

Chattree V, Khanna N, Rao D . Alterations in T cell signal transduction by M. leprae antigens is associated with downregulation of second messengers PKC, calcium, calcineurin, MAPK and various transcription factors in leprosy patients. Mol Immunol. 2006; 44(8):2066-77. DOI: 10.1016/j.molimm.2006.09.008. View